-
1
-
-
0023717986
-
Staging and prognosis in chronic myelogenous leukemia
-
Sokal J.E., Baccarani M., Russo D., et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25 (1988) 49-61
-
(1988)
Semin Hematol
, vol.25
, pp. 49-61
-
-
Sokal, J.E.1
Baccarani, M.2
Russo, D.3
-
2
-
-
0027992614
-
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia
-
Clift R.A., Buckner C.D., Thomas E.D., et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 84 (1994) 4368-4373
-
(1994)
Blood
, vol.84
, pp. 4368-4373
-
-
Clift, R.A.1
Buckner, C.D.2
Thomas, E.D.3
-
3
-
-
0023841366
-
Characteristics of accelerated disease in chronic myelogenous leukemia
-
Kantarjian H.M., Dixon D., Keating M.J., et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61 (1988) 1441-1446
-
(1988)
Cancer
, vol.61
, pp. 1441-1446
-
-
Kantarjian, H.M.1
Dixon, D.2
Keating, M.J.3
-
4
-
-
0021344640
-
Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia
-
Speck B., Bortin M.M., Champlin R., et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet 1 (1984) 665-668
-
(1984)
Lancet
, vol.1
, pp. 665-668
-
-
Speck, B.1
Bortin, M.M.2
Champlin, R.3
-
6
-
-
0031785825
-
Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
-
Cortes J., Talpaz M., O'Brien S., et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol 16 (1998) 3279-3285
-
(1998)
J Clin Oncol
, vol.16
, pp. 3279-3285
-
-
Cortes, J.1
Talpaz, M.2
O'Brien, S.3
-
7
-
-
0030061157
-
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia
-
Majlis A., Smith T.L., Talpaz M., et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 14 (1996) 196-203
-
(1996)
J Clin Oncol
, vol.14
, pp. 196-203
-
-
Majlis, A.1
Smith, T.L.2
Talpaz, M.3
-
8
-
-
0023753576
-
The molecular genetics of Philadelphia chromosome-positive leukemias
-
Kurzrock R., Gutterman J.U., and Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319 (1988) 990-998
-
(1988)
N Engl J Med
, vol.319
, pp. 990-998
-
-
Kurzrock, R.1
Gutterman, J.U.2
Talpaz, M.3
-
9
-
-
33644525274
-
Gene expression changes associated with progression and response in chronic myeloid leukemia
-
Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103 (2006) 2794-2799
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 2794-2799
-
-
Radich, J.P.1
Dai, H.2
Mao, M.3
-
10
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
-
11
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
-
12
-
-
40749113711
-
-
Gleevec Package insert. East Hanover, NJ. Novartis Pharmaceuticals Corporation
-
Gleevec Package insert. East Hanover, NJ. Novartis Pharmaceuticals Corporation
-
-
-
-
13
-
-
0037186915
-
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
-
Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
-
(2002)
N Engl J Med
, vol.346
, pp. 645-652
-
-
Kantarjian, H.1
Sawyers, C.2
Hochhaus, A.3
-
14
-
-
33746845181
-
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
-
Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 (2006) 908-916
-
(2006)
Nat Med
, vol.12
, pp. 908-916
-
-
Kerkela, R.1
Grazette, L.2
Yacobi, R.3
-
15
-
-
34548030470
-
Congestive heart failure is a rare event in patients receiving imatinib therapy
-
Atallah E., Durand J.-B., Kantarjian H., et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110 (2007) 1233-1237
-
(2007)
Blood
, vol.110
, pp. 1233-1237
-
-
Atallah, E.1
Durand, J.-B.2
Kantarjian, H.3
-
16
-
-
33747154547
-
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
-
Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
-
(2006)
Blood
, vol.108
, pp. 1809-1820
-
-
Baccarani, M.1
Saglio, G.2
Goldman, J.3
-
17
-
-
0033572876
-
Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
-
Sacchi S., Kantarjian H.M., O'Brien S., et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86 (1999) 2632-2641
-
(1999)
Cancer
, vol.86
, pp. 2632-2641
-
-
Sacchi, S.1
Kantarjian, H.M.2
O'Brien, S.3
-
20
-
-
33646013280
-
The effect of prior exposure to imatinib on transplant-related mortality
-
Deininger M., Schleuning M., Greinix H., et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 91 (2006) 452-459
-
(2006)
Haematologica
, vol.91
, pp. 452-459
-
-
Deininger, M.1
Schleuning, M.2
Greinix, H.3
-
21
-
-
0037085785
-
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study
-
Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99 (2002) 1928-1937
-
(2002)
Blood
, vol.99
, pp. 1928-1937
-
-
Talpaz, M.1
Silver, R.T.2
Druker, B.J.3
-
22
-
-
18044371828
-
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-Comparison with historic experience
-
Kantarjian H., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-Comparison with historic experience. Cancer 103 (2005) 2099-2108
-
(2005)
Cancer
, vol.103
, pp. 2099-2108
-
-
Kantarjian, H.1
Talpaz, M.2
O'Brien, S.3
-
23
-
-
0037093092
-
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study
-
Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99 (2002) 3530-3539
-
(2002)
Blood
, vol.99
, pp. 3530-3539
-
-
Sawyers, C.L.1
Hochhaus, A.2
Feldman, E.3
-
24
-
-
0037105560
-
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
-
Ottmann O.G., Druker B.J., Sawyers C.L., et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100 (2002) 1965-1971
-
(2002)
Blood
, vol.100
, pp. 1965-1971
-
-
Ottmann, O.G.1
Druker, B.J.2
Sawyers, C.L.3
-
25
-
-
20144388183
-
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up
-
Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 103 (2005) 1659-1669
-
(2005)
Cancer
, vol.103
, pp. 1659-1669
-
-
Lahaye, T.1
Riehm, B.2
Berger, U.3
-
26
-
-
27244437924
-
New targeted approaches in chronic myeloid leukemia
-
Cortes J., and Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol 23 (2005) 6316-6324
-
(2005)
J Clin Oncol
, vol.23
, pp. 6316-6324
-
-
Cortes, J.1
Kantarjian, H.2
-
27
-
-
0033614446
-
Chronic myeloid leukemia
-
Sawyers C.L. Chronic myeloid leukemia. N Engl J Med 340 (1999) 1330-1340
-
(1999)
N Engl J Med
, vol.340
, pp. 1330-1340
-
-
Sawyers, C.L.1
-
29
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
-
(2001)
Science
, vol.293
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
-
30
-
-
0036678472
-
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop
-
Roumiantsev S., Shah N.P., Gorre M.E., et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 99 (2002) 10700-10705
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 10700-10705
-
-
Roumiantsev, S.1
Shah, N.P.2
Gorre, M.E.3
-
31
-
-
0037438467
-
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
-
Kantarjian H.M., Talpaz M., O'Brien S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2003) 473-475
-
(2003)
Blood
, vol.101
, pp. 473-475
-
-
Kantarjian, H.M.1
Talpaz, M.2
O'Brien, S.3
-
32
-
-
33747605541
-
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis
-
Olsson-Stromberg U., Aleskog A., Bjornberg A., et al. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis. Anticancer Drugs 17 (2006) 631-639
-
(2006)
Anticancer Drugs
, vol.17
, pp. 631-639
-
-
Olsson-Stromberg, U.1
Aleskog, A.2
Bjornberg, A.3
-
33
-
-
0028170517
-
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia
-
German CML Study Group
-
Hehlmann R., Heimpel H., Hasford J., and German CML Study Group. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84 (1994) 4064-4477
-
(1994)
Blood
, vol.84
, pp. 4064-4477
-
-
Hehlmann, R.1
Heimpel, H.2
Hasford, J.3
-
34
-
-
0029041749
-
UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia
-
Allan N.C., Richards S.M., and Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345 (1995) 1392-1397
-
(1995)
Lancet
, vol.345
, pp. 1392-1397
-
-
Allan, N.C.1
Richards, S.M.2
Shepherd, P.C.3
-
35
-
-
0742322159
-
Interferons: Mechanisms of action and clinical applications
-
Parmar S., and Platanias L.C. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 15 (2003) 431-439
-
(2003)
Curr Opin Oncol
, vol.15
, pp. 431-439
-
-
Parmar, S.1
Platanias, L.C.2
-
36
-
-
0025868121
-
Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells
-
Dowding C., Guo A.P., Osterholz J., et al. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78 (1991) 499-505
-
(1991)
Blood
, vol.78
, pp. 499-505
-
-
Dowding, C.1
Guo, A.P.2
Osterholz, J.3
-
37
-
-
0029888021
-
Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
-
Bhatia R., McCarthy J.B., and Verfaillie C.M. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87 (1996) 3883-3891
-
(1996)
Blood
, vol.87
, pp. 3883-3891
-
-
Bhatia, R.1
McCarthy, J.B.2
Verfaillie, C.M.3
-
38
-
-
0031981132
-
Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia
-
Cortes J., Fayad L., Kantarjian H., et al. Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Leukemia 12 (1998) 455-462
-
(1998)
Leukemia
, vol.12
, pp. 455-462
-
-
Cortes, J.1
Fayad, L.2
Kantarjian, H.3
-
39
-
-
0035383771
-
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia
-
Deng M., and Daley G.Q. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 97 (2001) 3491-3497
-
(2001)
Blood
, vol.97
, pp. 3491-3497
-
-
Deng, M.1
Daley, G.Q.2
-
40
-
-
0031885797
-
Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon
-
Oka T., Sastry K.J., Nehete P., et al. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 12 (1998) 155-163
-
(1998)
Leukemia
, vol.12
, pp. 155-163
-
-
Oka, T.1
Sastry, K.J.2
Nehete, P.3
-
41
-
-
10244257546
-
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
-
Baccarani M., Martinelli G., Rosti G., et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104 (2004) 4245-4251
-
(2004)
Blood
, vol.104
, pp. 4245-4251
-
-
Baccarani, M.1
Martinelli, G.2
Rosti, G.3
-
42
-
-
40749133449
-
Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): A randomized trial of frontline high-dose (HS) imatinib mesylate (IM) with or without pegylated-interferon (PEG-IFN) and GM-CSF
-
(abstr 2207)
-
Quintas-Cardama A., Kantarjian H.M., Ravandi F., et al. Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): A randomized trial of frontline high-dose (HS) imatinib mesylate (IM) with or without pegylated-interferon (PEG-IFN) and GM-CSF. Blood 11 (2006) 626a (abstr 2207)
-
(2006)
Blood
, vol.11
-
-
Quintas-Cardama, A.1
Kantarjian, H.M.2
Ravandi, F.3
-
43
-
-
33748865368
-
IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4
-
Dauer M., Schmad K., Junkmann J., et al. IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J Leukoc Biol 80 (2006) 278-286
-
(2006)
J Leukoc Biol
, vol.80
, pp. 278-286
-
-
Dauer, M.1
Schmad, K.2
Junkmann, J.3
-
44
-
-
33744792003
-
Randomized comparison of imatinib with imatinib combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase: Design and first interim analysis of a phase III trial from the French CML Group
-
(abstr 168)
-
Guerci A., Nicolini F., Maloisel F., et al. Randomized comparison of imatinib with imatinib combination therapies in newly diagnosed chronic myelogenous leukemia patients in chronic phase: Design and first interim analysis of a phase III trial from the French CML Group. Blood 11 (2005) 53a (abstr 168)
-
(2005)
Blood
, vol.11
-
-
Guerci, A.1
Nicolini, F.2
Maloisel, F.3
-
45
-
-
0345696854
-
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
-
French Chronic Myeloid Leukemia Study Group
-
Guilhot F., Chastang C., Michallet M., and French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337 (1997) 223-229
-
(1997)
N Engl J Med
, vol.337
, pp. 223-229
-
-
Guilhot, F.1
Chastang, C.2
Michallet, M.3
-
46
-
-
33845301827
-
A pilot trial of imatinib, low-dose cytarabine (ara-C) and idarubicin (Ida) in patients (pts) with chronic myeloid leukemia (CML) in myeloid blastic phase (BP)
-
(abstr 4840)
-
Quintas-Cardama A., Kantarjian H., Ravandi F., et al. A pilot trial of imatinib, low-dose cytarabine (ara-C) and idarubicin (Ida) in patients (pts) with chronic myeloid leukemia (CML) in myeloid blastic phase (BP). Blood 11 (2005) 290a (abstr 4840)
-
(2005)
Blood
, vol.11
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
Ravandi, F.3
-
47
-
-
40749153231
-
Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C (LDAC) and imatinib
-
(abstr 1853)
-
Heidel F., Cortes J., Ruecker F., et al. Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C (LDAC) and imatinib. Blood 11 (2005) 527a (abstr 1853)
-
(2005)
Blood
, vol.11
-
-
Heidel, F.1
Cortes, J.2
Ruecker, F.3
-
48
-
-
33845743957
-
Aurora kinases: New targets for cancer therapy
-
Carvajal R.D., Tse A., and Schwartz G.K. Aurora kinases: New targets for cancer therapy. Clin Cancer Res 12 (2006) 6869-6875
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6869-6875
-
-
Carvajal, R.D.1
Tse, A.2
Schwartz, G.K.3
-
49
-
-
2342639645
-
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
-
Harrington E.A., Bebbington D., Moore J., et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10 (2004) 262-267
-
(2004)
Nat Med
, vol.10
, pp. 262-267
-
-
Harrington, E.A.1
Bebbington, D.2
Moore, J.3
-
50
-
-
34247615972
-
Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680
-
Cheetham G.M., Charlton P.A., Golec J.M., et al. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 251 (2007) 323-329
-
(2007)
Cancer Lett
, vol.251
, pp. 323-329
-
-
Cheetham, G.M.1
Charlton, P.A.2
Golec, J.M.3
-
51
-
-
33845474871
-
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
-
(abstr 1967)
-
Giles F.J., Cortes J.E., Jones D., et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 11 (2006) 556a (abstr 1967)
-
(2006)
Blood
, vol.11
-
-
Giles, F.J.1
Cortes, J.E.2
Jones, D.3
-
52
-
-
33846559929
-
Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, ara-C, and inhibitors of BCR-ABL
-
(abstr 1384)
-
Hoover R.R., and Harding M.W. Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, ara-C, and inhibitors of BCR-ABL. Blood 11 (2006) 403a (abstr 1384)
-
(2006)
Blood
, vol.11
-
-
Hoover, R.R.1
Harding, M.W.2
-
53
-
-
0028787176
-
Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
-
O'Brien S., Kantarjian H., Keating M., et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86 (1995) 3322-3326
-
(1995)
Blood
, vol.86
, pp. 3322-3326
-
-
O'Brien, S.1
Kantarjian, H.2
Keating, M.3
-
54
-
-
0030991556
-
Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors
-
Visani G., Russo D., Ottaviani E., et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia 11 (1997) 624-628
-
(1997)
Leukemia
, vol.11
, pp. 624-628
-
-
Visani, G.1
Russo, D.2
Ottaviani, E.3
-
55
-
-
0041887168
-
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
-
O'Brien S., Giles F., Talpz M., et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 98 (2003) 888-893
-
(2003)
Cancer
, vol.98
, pp. 888-893
-
-
O'Brien, S.1
Giles, F.2
Talpz, M.3
-
56
-
-
0037094118
-
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
-
Scappini B., Onida F., Kantarjian H.M., et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 94 (2002) 2653-2662
-
(2002)
Cancer
, vol.94
, pp. 2653-2662
-
-
Scappini, B.1
Onida, F.2
Kantarjian, H.M.3
-
57
-
-
0036940590
-
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs
-
Tipping A.J., Mahon F.X., Zafirides G., et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 16 (2002) 2349-2357
-
(2002)
Leukemia
, vol.16
, pp. 2349-2357
-
-
Tipping, A.J.1
Mahon, F.X.2
Zafirides, G.3
-
58
-
-
33846261532
-
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
-
Quintás-Cardama A., Kantarrjian H., Garcia-Manero G., et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109 (2007) 1701-1707
-
(2007)
Cancer
, vol.109
, pp. 1701-1707
-
-
Quintás-Cardama, A.1
Kantarrjian, H.2
Garcia-Manero, G.3
-
59
-
-
33845328611
-
A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML)
-
(abstr 2174)
-
Quintas-Cardama A., Kantarjian H.M., Wierda W., et al. A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML). Blood 11 (2006) 616a (abstr 2174)
-
(2006)
Blood
, vol.11
-
-
Quintas-Cardama, A.1
Kantarjian, H.M.2
Wierda, W.3
-
60
-
-
0034743735
-
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells
-
Porosnicu M., Nimmanapalli R., Nguyen D., et al. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 15 (2001) 772-778
-
(2001)
Leukemia
, vol.15
, pp. 772-778
-
-
Porosnicu, M.1
Nimmanapalli, R.2
Nguyen, D.3
-
61
-
-
40749149283
-
Comparison of combination therapy of imatinib with trisenox versus imatinib monotherapy for chronic myeloid leukemia patients in chronic phase
-
(abstr 2159)
-
Yang D., Zhang R., Shen Y., et al. Comparison of combination therapy of imatinib with trisenox versus imatinib monotherapy for chronic myeloid leukemia patients in chronic phase. Blood 11 (2006) 612a (abstr 2159)
-
(2006)
Blood
, vol.11
-
-
Yang, D.1
Zhang, R.2
Shen, Y.3
-
62
-
-
0025810272
-
Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae
-
Schnier J., Schwelberger H.G., Smit-McBride Z., et al. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast Saccharomyces cerevisiae. Mol Cell Biol 11 (1991) 3105-3114
-
(1991)
Mol Cell Biol
, vol.11
, pp. 3105-3114
-
-
Schnier, J.1
Schwelberger, H.G.2
Smit-McBride, Z.3
-
63
-
-
33846939244
-
Hypusination of eukaryotic initiation factor 5A (EIF-5A): A novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach
-
Balabanov S., Gontarewicz A., Ziegler P., et al. Hypusination of eukaryotic initiation factor 5A (EIF-5A): A novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 109 (2007) 1701-1707
-
(2007)
Blood
, vol.109
, pp. 1701-1707
-
-
Balabanov, S.1
Gontarewicz, A.2
Ziegler, P.3
-
64
-
-
3242779326
-
Investigational strategies in chronic myelogenous leukemia
-
ix
-
Cortes J.E., O'Brien S.M., Giles F., et al. Investigational strategies in chronic myelogenous leukemia. ix. Hematol Oncol Clin North Am 18 (2004) 619-639
-
(2004)
Hematol Oncol Clin North Am
, vol.18
, pp. 619-639
-
-
Cortes, J.E.1
O'Brien, S.M.2
Giles, F.3
-
65
-
-
33745888156
-
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
-
Fiskus W., Pranpat M., Bali P., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 108 (2006) 645-652
-
(2006)
Blood
, vol.108
, pp. 645-652
-
-
Fiskus, W.1
Pranpat, M.2
Bali, P.3
-
66
-
-
20844444898
-
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
-
George P., Bali P., Annavarapu S., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105 (2005) 1768-1776
-
(2005)
Blood
, vol.105
, pp. 1768-1776
-
-
George, P.1
Bali, P.2
Annavarapu, S.3
-
67
-
-
33750463070
-
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
-
Kano Y., Akutsu M., Tsunoda S., et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest New Drugs 25 (2007) 31-40
-
(2007)
Invest New Drugs
, vol.25
, pp. 31-40
-
-
Kano, Y.1
Akutsu, M.2
Tsunoda, S.3
-
68
-
-
27144551665
-
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo
-
Stover E.H., Chen J., Lee B.H., et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 106 (2005) 3206-3213
-
(2005)
Blood
, vol.106
, pp. 3206-3213
-
-
Stover, E.H.1
Chen, J.2
Lee, B.H.3
-
69
-
-
38949096781
-
Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes
-
Garcia-Manero G., Yang H., Bueso-Ramos C., et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
-
(2008)
Blood
, vol.111
, pp. 1060-1066
-
-
Garcia-Manero, G.1
Yang, H.2
Bueso-Ramos, C.3
-
70
-
-
33745307617
-
Ras, PI(3)K and mTOR signalling controls tumour cell growth
-
Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
-
(2006)
Nature
, vol.441
, pp. 424-430
-
-
Shaw, R.J.1
Cantley, L.C.2
-
71
-
-
34548799800
-
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
-
Cortes J., Jabbour E., Daley G.Q., et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110 (2007) 1295-1302
-
(2007)
Cancer
, vol.110
, pp. 1295-1302
-
-
Cortes, J.1
Jabbour, E.2
Daley, G.Q.3
-
72
-
-
0043288724
-
Heat shock protein 90 as a molecular target for cancer therapeutics
-
Isaacs J.S., Xu W., and Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3 (2003) 213-217
-
(2003)
Cancer Cell
, vol.3
, pp. 213-217
-
-
Isaacs, J.S.1
Xu, W.2
Neckers, L.3
-
73
-
-
2442695516
-
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3
-
George P., Bali P., Cohen P., et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64 (2004) 3645-3652
-
(2004)
Cancer Res
, vol.64
, pp. 3645-3652
-
-
George, P.1
Bali, P.2
Cohen, P.3
-
74
-
-
0037111665
-
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin
-
Mayerhofer M., Valent P., Sperr W.R., et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100 (2002) 3767-3775
-
(2002)
Blood
, vol.100
, pp. 3767-3775
-
-
Mayerhofer, M.1
Valent, P.2
Sperr, W.R.3
-
75
-
-
0141508021
-
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin
-
Ly C., Arechiga A.F., Melo J.V., et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63 (2003) 5716-5722
-
(2003)
Cancer Res
, vol.63
, pp. 5716-5722
-
-
Ly, C.1
Arechiga, A.F.2
Melo, J.V.3
-
76
-
-
1542327671
-
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
-
Mohi M.G., Boulton C., Gu T.L., et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 101 (2004) 3130-3135
-
(2004)
Proc Natl Acad Sci U S A
, vol.101
, pp. 3130-3135
-
-
Mohi, M.G.1
Boulton, C.2
Gu, T.L.3
-
77
-
-
27144526660
-
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
-
Burchert A., Wng Y., Cai D., et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19 (2005) 1774-1782
-
(2005)
Leukemia
, vol.19
, pp. 1774-1782
-
-
Burchert, A.1
Wng, Y.2
Cai, D.3
-
78
-
-
33947224197
-
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
-
Kantarjian H.M., Talpaz M., Giles F., et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145 (2006) 913-923
-
(2006)
Ann Intern Med
, vol.145
, pp. 913-923
-
-
Kantarjian, H.M.1
Talpaz, M.2
Giles, F.3
-
79
-
-
30844433972
-
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia
-
Hughes T., and Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 20 (2006) 29-41
-
(2006)
Blood Rev
, vol.20
, pp. 29-41
-
-
Hughes, T.1
Branford, S.2
-
80
-
-
27144509746
-
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
-
White D., Saunders V., Lyons A.B., et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 106 (2005) 2520-2526
-
(2005)
Blood
, vol.106
, pp. 2520-2526
-
-
White, D.1
Saunders, V.2
Lyons, A.B.3
-
81
-
-
0028024938
-
Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia
-
ten Hoeve J., Arlinghaus R.B., Guo J.Q., et al. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia. Blood 84 (1994) 1731-1736
-
(1994)
Blood
, vol.84
, pp. 1731-1736
-
-
ten Hoeve, J.1
Arlinghaus, R.B.2
Guo, J.Q.3
-
82
-
-
33745085275
-
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
-
White D.L., Saunders V.A., Dang P., et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108 (2006) 697-704
-
(2006)
Blood
, vol.108
, pp. 697-704
-
-
White, D.L.1
Saunders, V.A.2
Dang, P.3
-
83
-
-
9444282642
-
Active transport of imatinib into and out of cells: Implications for drug resistance
-
Thomas J., Wang L., Clark R.E., et al. Active transport of imatinib into and out of cells: Implications for drug resistance. Blood 104 (2004) 3739-3745
-
(2004)
Blood
, vol.104
, pp. 3739-3745
-
-
Thomas, J.1
Wang, L.2
Clark, R.E.3
-
84
-
-
24644435728
-
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
-
Golemovic M., Verstovsek S., Giles F., et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11 (2005) 4941-4947
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4941-4947
-
-
Golemovic, M.1
Verstovsek, S.2
Giles, F.3
-
85
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
86
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
O'Hare T., Walters D.K., Stoffregen E.P., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65 (2005) 4500-4505
-
(2005)
Cancer Res
, vol.65
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
-
87
-
-
24644464172
-
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
-
Verstovsek S., Golemovic M., Kantarjian H., et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104 (2005) 1230-1236
-
(2005)
Cancer
, vol.104
, pp. 1230-1236
-
-
Verstovsek, S.1
Golemovic, M.2
Kantarjian, H.3
-
88
-
-
33745283618
-
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
-
Tokarski J.S., Newit J.A., Chang C.Y., et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66 (2006) 5790-5797
-
(2006)
Cancer Res
, vol.66
, pp. 5790-5797
-
-
Tokarski, J.S.1
Newit, J.A.2
Chang, C.Y.3
-
89
-
-
33947280081
-
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
-
Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
-
(2007)
Blood
, vol.109
, pp. 2303-2309
-
-
Hochhaus, A.1
Kantarjian, H.M.2
Baccarani, M.3
-
90
-
-
34247465126
-
Efficacy of dasatinib (Sprycel) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 'START-C' phase II study
-
(abstr 164)
-
Baccarani M., Kantarjian H.M., Apperley J.F., et al. Efficacy of dasatinib (Sprycel) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 'START-C' phase II study. Blood 108 (2006) 53a (abstr 164)
-
(2006)
Blood
, vol.108
-
-
Baccarani, M.1
Kantarjian, H.M.2
Apperley, J.F.3
-
91
-
-
33846801845
-
Dasatinib (SPRYCEL(R)) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): Updated results from the CA180-015 'START-L' study
-
(abstr 286)
-
Dombret H., Ottmann O.G., Rosti G., et al. Dasatinib (SPRYCEL(R)) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): Updated results from the CA180-015 'START-L' study. Blood 11 (2006) 88a (abstr 286)
-
(2006)
Blood
, vol.11
-
-
Dombret, H.1
Ottmann, O.G.2
Rosti, G.3
-
92
-
-
33846819360
-
Dasatinib (SPRYCEL(R)) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i)
-
(abstr 745)
-
Martinelli G., Hochhaus A., Coutre S., et al. Dasatinib (SPRYCEL(R)) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i). Blood 11 (2006) 224a (abstr 745)
-
(2006)
Blood
, vol.11
-
-
Martinelli, G.1
Hochhaus, A.2
Coutre, S.3
-
93
-
-
34247543905
-
Dasatinib (Sprycel) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): Updated results of the CA180-005 'START-A' phase II study
-
(abstr 2160)
-
Cortes J., Kim D.W., Guilhot F., et al. Dasatinib (Sprycel) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): Updated results of the CA180-005 'START-A' phase II study. Blood 108 (2006) 613a (abstr 2160)
-
(2006)
Blood
, vol.108
-
-
Cortes, J.1
Kim, D.W.2
Guilhot, F.3
-
94
-
-
34248324467
-
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
-
Guilhot F., Apperley J., Kim D.W., et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109 (2007) 4143-4150
-
(2007)
Blood
, vol.109
, pp. 4143-4150
-
-
Guilhot, F.1
Apperley, J.2
Kim, D.W.3
-
95
-
-
33947356135
-
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
-
Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109 (2007) 3207-3213
-
(2007)
Blood
, vol.109
, pp. 3207-3213
-
-
Cortes, J.1
Rousselot, P.2
Kim, D.W.3
-
96
-
-
33745114173
-
AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL
-
Weisberg E., Manley P., Mestan J., et al. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 94 (2006) 1765-1769
-
(2006)
Br J Cancer
, vol.94
, pp. 1765-1769
-
-
Weisberg, E.1
Manley, P.2
Mestan, J.3
-
97
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546
-
(2007)
Blood
, vol.110
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
-
98
-
-
33846812048
-
A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
-
(abstr 2169)
-
Kantarjian H.M., Gattermann N., Hochhaus A., et al. A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). Blood 11 (2006) 615a (abstr 2169)
-
(2006)
Blood
, vol.11
-
-
Kantarjian, H.M.1
Gattermann, N.2
Hochhaus, A.3
-
99
-
-
43549116467
-
Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance
-
(abstr 735)
-
Kantarjian H. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood 11 (2006) 226a (abstr 735)
-
(2006)
Blood
, vol.11
-
-
Kantarjian, H.1
-
100
-
-
40749142103
-
Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance
-
(abstr 471)
-
Coutre P.L. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. Blood 11 (2006) 145a (abstr 471)
-
(2006)
Blood
, vol.11
-
-
Coutre, P.L.1
-
101
-
-
43549112174
-
Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
-
(abstr 1025)
-
Giles F. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 11 (2006) 310a (abstr 1025)
-
(2006)
Blood
, vol.11
-
-
Giles, F.1
-
102
-
-
36048948259
-
A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory PH+ acute lymphoblastic leukemia (ALL)
-
(abstr 7040)
-
Larson R., Ottman O., Kantarjian H., et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory PH+ acute lymphoblastic leukemia (ALL). J Clin Oncol 25 (2007) 367s (abstr 7040)
-
(2007)
J Clin Oncol
, vol.25
-
-
Larson, R.1
Ottman, O.2
Kantarjian, H.3
-
103
-
-
40749096561
-
A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy
-
(abstr 2170)
-
Giles F., le Coutre P., Bhalla K., et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy. Blood 11 (2006) 645a (abstr 2170)
-
(2006)
Blood
, vol.11
-
-
Giles, F.1
le Coutre, P.2
Bhalla, K.3
-
104
-
-
39049158657
-
Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib
-
(abstr 7006)
-
Gambacorti-Passerini C., Brummendorf T., Kantarjian H., et al. Bosutinib (SKI-606) exhibits clinical activity in patients with Philadelphia chromosome positive CML or ALL who failed imatinib. J Clin Oncol 25 (2007) 18S (abstr 7006)
-
(2007)
J Clin Oncol
, vol.25
-
-
Gambacorti-Passerini, C.1
Brummendorf, T.2
Kantarjian, H.3
-
105
-
-
39049164641
-
A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
-
(abstr 7046)
-
Craig A., Kantarjian H., Cortes J., et al. A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib. J Clin Oncol 25 (2007) 18S (abstr 7046)
-
(2007)
J Clin Oncol
, vol.25
-
-
Craig, A.1
Kantarjian, H.2
Cortes, J.3
-
106
-
-
18144451171
-
Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders
-
Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
-
(2001)
Blood
, vol.98
, pp. 3074-3081
-
-
Bonifazi, F.1
de Vivo, A.2
Rosti, G.3
-
107
-
-
0036137923
-
Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa
-
Mahon F.X., Delbrel X., Cony-Makhoul P., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20 (2002) 214-220
-
(2002)
J Clin Oncol
, vol.20
, pp. 214-220
-
-
Mahon, F.X.1
Delbrel, X.2
Cony-Makhoul, P.3
-
108
-
-
0032748325
-
Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
-
Branford S., Hughes T.P., and Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107 (1999) 587-599
-
(1999)
Br J Haematol
, vol.107
, pp. 587-599
-
-
Branford, S.1
Hughes, T.P.2
Rudzki, Z.3
-
109
-
-
4644341516
-
Discontinuation of imatinib therapy after achieving a molecular response
-
Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
-
(2004)
Blood
, vol.104
, pp. 2204-2205
-
-
Cortes, J.1
O'Brien, S.2
Kantarjian, H.3
-
110
-
-
22544459376
-
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation
-
Merante S., Orlandi E., Bernasconi P., et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90 (2005) 979-981
-
(2005)
Haematologica
, vol.90
, pp. 979-981
-
-
Merante, S.1
Orlandi, E.2
Bernasconi, P.3
-
111
-
-
33846023983
-
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
-
Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
-
(2007)
Blood
, vol.109
, pp. 58-60
-
-
Rousselot, P.1
Huguet, F.2
Rea, D.3
-
112
-
-
21744457612
-
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
-
Jorgensen H.G., Allan E.K., Graham S.M., et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19 (2005) 1184-1191
-
(2005)
Leukemia
, vol.19
, pp. 1184-1191
-
-
Jorgensen, H.G.1
Allan, E.K.2
Graham, S.M.3
-
113
-
-
0020216124
-
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome
-
Nusse R., and Varmus H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31 (1982) 99-109
-
(1982)
Cell
, vol.31
, pp. 99-109
-
-
Nusse, R.1
Varmus, H.E.2
-
114
-
-
33746808398
-
Wnt/beta-catenin signaling in development and disease
-
Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 127 (2006) 469-480
-
(2006)
Cell
, vol.127
, pp. 469-480
-
-
Clevers, H.1
-
115
-
-
27644573539
-
Malignant and premalignant lesions of the colon
-
Friedman S.L., McQuaid K.R., and Grendell J.H. (Eds), Lange Medical Books/McGraw-Hill, New York, NY
-
Bresalier R.S. Malignant and premalignant lesions of the colon. In: Friedman S.L., McQuaid K.R., and Grendell J.H. (Eds). Current Diagnosis and Treatment in Gastroenterology. 2nd ed (2003), Lange Medical Books/McGraw-Hill, New York, NY 407-435
-
(2003)
Current Diagnosis and Treatment in Gastroenterology. 2nd ed
, pp. 407-435
-
-
Bresalier, R.S.1
-
116
-
-
0027738023
-
Association of the APC gene product with beta-catenin
-
Rubinfeld B., Souza B., Albert I., et al. Association of the APC gene product with beta-catenin. Science 262 (1993) 1731-1734
-
(1993)
Science
, vol.262
, pp. 1731-1734
-
-
Rubinfeld, B.1
Souza, B.2
Albert, I.3
-
117
-
-
0030989287
-
A role for the Wnt gene family in hematopoiesis: Expansion of multilineage progenitor cells
-
Austin T.W., Solar G.P., Ziegler F.C., et al. A role for the Wnt gene family in hematopoiesis: Expansion of multilineage progenitor cells. Blood 89 (1997) 3624-3635
-
(1997)
Blood
, vol.89
, pp. 3624-3635
-
-
Austin, T.W.1
Solar, G.P.2
Ziegler, F.C.3
-
118
-
-
0032212190
-
Role of members of the Wnt gene family in human hematopoiesis
-
Van Den Berg D.J., Sharma A.K., Bruno E., et al. Role of members of the Wnt gene family in human hematopoiesis. Blood 92 (1998) 3189-3202
-
(1998)
Blood
, vol.92
, pp. 3189-3202
-
-
Van Den Berg, D.J.1
Sharma, A.K.2
Bruno, E.3
-
119
-
-
40749086473
-
Inhibition of chronic myelogenous leukemia stem cells with novel Wnt antagonists
-
(abstr 238)
-
Kavalerchik E., Gotlib J., Geron I., et al. Inhibition of chronic myelogenous leukemia stem cells with novel Wnt antagonists. Blood 11 (2006) 74a (abstr 238)
-
(2006)
Blood
, vol.11
-
-
Kavalerchik, E.1
Gotlib, J.2
Geron, I.3
-
120
-
-
0036098552
-
AP-1 as a regulator of cell life and death
-
Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4 (2002) E131-E136
-
(2002)
Nat Cell Biol
, vol.4
-
-
Shaulian, E.1
Karin, M.2
-
121
-
-
0033557740
-
JunB is essential for mammalian placentation
-
Schorpp-Kistner M., Wang Z.Q., Angel P., et al. JunB is essential for mammalian placentation. Embo J 18 (1999) 934-948
-
(1999)
Embo J
, vol.18
, pp. 934-948
-
-
Schorpp-Kistner, M.1
Wang, Z.Q.2
Angel, P.3
-
122
-
-
0035846912
-
Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage
-
Passegue E., Jochum W., Schorpp-Kistner M., et al. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. Cell 104 (2001) 21-32
-
(2001)
Cell
, vol.104
, pp. 21-32
-
-
Passegue, E.1
Jochum, W.2
Schorpp-Kistner, M.3
-
123
-
-
0038281349
-
JunB gene expression is inactivated by methylation in chronic myeloid leukemia
-
Yang M.Y., Liu T.C., Chang J.G., et al. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101 (2003) 3205-3211
-
(2003)
Blood
, vol.101
, pp. 3205-3211
-
-
Yang, M.Y.1
Liu, T.C.2
Chang, J.G.3
-
124
-
-
33748125557
-
The regulation of chromatin and DNA-methylation patterns in blood cell development
-
Bonifer C., Lefevre P., and Tagoh H. The regulation of chromatin and DNA-methylation patterns in blood cell development. Curr Top Microbiol Immunol 310 (2006) 1-12
-
(2006)
Curr Top Microbiol Immunol
, vol.310
, pp. 1-12
-
-
Bonifer, C.1
Lefevre, P.2
Tagoh, H.3
-
125
-
-
29144517352
-
Decitabine: A historical review of the development of an epigenetic drug
-
de Vos D., and van Overveld W. Decitabine: A historical review of the development of an epigenetic drug. Ann Hematol 84 suppl (2005) 3-8
-
(2005)
Ann Hematol
, vol.84
, Issue.SUPPL
, pp. 3-8
-
-
de Vos, D.1
van Overveld, W.2
-
126
-
-
21244431605
-
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
-
Issa J.P., Gharibyan V., Cortes J., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
-
(2005)
J Clin Oncol
, vol.23
, pp. 3948-3956
-
-
Issa, J.P.1
Gharibyan, V.2
Cortes, J.3
-
127
-
-
9144271748
-
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines
-
La Rosee P., Johnson K., Corbin A.S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103 (2004) 208-215
-
(2004)
Blood
, vol.103
, pp. 208-215
-
-
La Rosee, P.1
Johnson, K.2
Corbin, A.S.3
-
128
-
-
33750370444
-
MicroRNA signatures in human cancers
-
Calin G.A., and Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 6 (2006) 857-866
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 857-866
-
-
Calin, G.A.1
Croce, C.M.2
-
129
-
-
20444460289
-
MicroRNA expression profiles classify human cancers
-
Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 435 (2005) 834-838
-
(2005)
Nature
, vol.435
, pp. 834-838
-
-
Lu, J.1
Getz, G.2
Miska, E.A.3
-
130
-
-
20444467290
-
A microRNA polycistron as a potential human oncogene
-
He L., Thomson J.M., Hemann M.T., et al. A microRNA polycistron as a potential human oncogene. Nature 435 (2005) 828-833
-
(2005)
Nature
, vol.435
, pp. 828-833
-
-
He, L.1
Thomson, J.M.2
Hemann, M.T.3
-
131
-
-
36549060409
-
The polycistronic miRNA cluster miR-17-92 is over-expressed in early phase chronic myeloid leukemia (CML) CD34+ cells
-
(abstr 741)
-
Venturini L., Battmer K., Castoldi M., et al. The polycistronic miRNA cluster miR-17-92 is over-expressed in early phase chronic myeloid leukemia (CML) CD34+ cells. Blood 11 (2006) 223a (abstr 741)
-
(2006)
Blood
, vol.11
-
-
Venturini, L.1
Battmer, K.2
Castoldi, M.3
|